Skip to main content

Combination Strategies

Section edited by Paolo A. Ascierto

This section aims to provide a focal point for research that highlights combination therapies, where two or more medications or therapies are strategically combined to improve the treatment of cancer, chronic infections, transplantation and potentially other complex and multi-factorial diseases.

Increasingly detailed understanding of the molecular basis driving complex disease has led to the identifications of new agents that target specific pathways. In some cases treatment of appropriately selected patients has led to striking clinical response, however both primary and secondary resistance mechanisms limited the success of many of these agents. It has become clear that combining or sequencing treatment modalities may enrich the communication between basic biological and immunological sciences and the clinical investigation arena.

Page 2 of 5

  1. Aberrant PI3K signalling is implicated in trastuzumab resistance in HER2-positive gastric cancer (GC). The role of PI3K or MEK inhibitors in sensitising HER2-positive GCs to trastuzumab or in overcoming trastu...

    Authors: M. Janusz Mezynski, Angela M. Farrelly, Mattia Cremona, Aoife Carr, Clare Morgan, Julie Workman, Paul Armstrong, Jennifer McAuley, Stephen Madden, Joanna Fay, Katherine M. Sheehan, Elaine W. Kay, Ciara Holohan, Yasir Elamin, Shereen Rafee, Patrick G. Morris…
    Citation: Journal of Translational Medicine 2021 19:184
  2. Sarcomas are rare, ubiquitous and heterogeneous tumors usually treated with surgery, chemotherapy, target therapy, and radiotherapy. However, 25–50% of patients experience local relapses and/or distant metasta...

    Authors: Ottavia Clemente, Alessandro Ottaiano, Giuseppe Di Lorenzo, Alessandra Bracigliano, Sabrina Lamia, Lucia Cannella, Antonio Pizzolorusso, Massimiliano Di Marzo, Mariachiara Santorsola, Annarosaria De Chiara, Flavio Fazioli and Salvatore Tafuto
    Citation: Journal of Translational Medicine 2021 19:173
  3. Lactate dehydrogenase A (LDHA) is overexpressed and associated with poor prognosis in many kinds of cancer. In the current study, we evaluated the prognostic value of LDHA expression in non-small cell lung cancer...

    Authors: Yang Yang, Yu Chong, Mengyuan Chen, Wumin Dai, Xia Zhou, Yongling Ji, Guoqin Qiu and Xianghui Du
    Citation: Journal of Translational Medicine 2021 19:170
  4. Gut microbiota has been reported to be disrupted by cisplatin, as well as to modulate chemotherapy toxicity. However, the precise role of intestinal microbiota in the pathogenesis of cisplatin hepatotoxicity r...

    Authors: Shenhai Gong, Yinglin Feng, Yunong Zeng, Huanrui Zhang, Meiping Pan, Fangjie He, Rong Wu, Jingrui Chen, Jiuling Lu, Siyou Zhang, Songhua Yuan and Xia Chen
    Citation: Journal of Translational Medicine 2021 19:147
  5. The Great Debate session at the 2020 Melanoma Bridge virtual congress (December 3rd–5th, Italy) featured counterpoint views from experts on five specific controversial issues in melanoma. The debates considere...

    Authors: Paolo A. Ascierto, Michael B. Atkins, Alexander M. Eggermont, Jeffrey E. Gershenwald, Jean-Jacques Grob, Omid Hamid, Vernon K. Sondak, Jeffrey A. Sosman, Hussein A. Tawbi, Jeffrey S. Weber, Corrado Caracò, Iman Osman and Igor Puzanov
    Citation: Journal of Translational Medicine 2021 19:142
  6. Coronavirus disease 2019 (COVID-19) global pandemic has created unique challenges to healthcare systems throughout the world. Ensuring subjects’ safety is mandatory especially in oncology, in consideration of ...

    Authors: Maria Antonietta Isgrò, Maria Grazia Vitale, Egidio Celentano, Flavia Nocerino, Giuseppe Porciello, Marcello Curvietto, Domenico Mallardo, Concetta Montagnese, Luigi Russo, Nicoletta Zanaletti, Antonio Avallone, Matilde Pensabene, Michelino De Laurentiis, Sara Centonze, Sandro Pignata, Lucia Cannella…
    Citation: Journal of Translational Medicine 2021 19:132
  7. The response to immunotherapy can be impaired by several factors including external intervention such as drug interactions with immune system. We aimed to examine the immunomodulatory action of opioids, since ...

    Authors: Andrea Botticelli, Alessio Cirillo, Giulia Pomati, Bruna Cerbelli, Simone Scagnoli, Michela Roberto, Alain Gelibter, Giulia Mammone, Maria Letizia Calandrella, Edoardo Cerbelli, Francesca Romana Di Pietro, Federica De Galitiis, Gaetano Lanzetta, Enrico Cortesi, Silvia Mezi and Paolo Marchetti
    Citation: Journal of Translational Medicine 2021 19:119

    The Letter to the Editor to this article has been published in Journal of Translational Medicine 2022 20:165

    The Letter to the Editor to this article has been published in Journal of Translational Medicine 2021 19:160

  8. Exosomes are nanoparticle sized (100 ± 50 nm) extracellular vesicles (ECVs) that play important roles in cell-to-cell communication. They do this by utilizing their natural ability to shuttle signaling molecul...

    Authors: Michael J. Gonzalez, Mercedes F. Kweh, Pier Mario Biava, Jose Olalde, Alondra P. Toro, Pascal J. Goldschmidt-Clermont and Ian A. White
    Citation: Journal of Translational Medicine 2021 19:103
  9. The Sars-CoV-2 can cause severe pneumonia with multiorgan disease; thus, the identification of clinical and laboratory predictors of the progression towards severe and fatal forms of this illness is needed. He...

    Authors: Flavia Biamonte, Cirino Botta, Maria Mazzitelli, Salvatore Rotundo, Enrico Maria Trecarichi, Daniela Foti, Carlo Torti, Giuseppe Viglietto, Daniele Torella and Francesco Costanzo
    Citation: Journal of Translational Medicine 2021 19:79
  10. The incidence of Merkel cell carcinoma (MCC), a rare form of skin cancer with a poor prognosis, has increased in Italy in recent decades. Avelumab, an anti-programmed death ligand 1 monoclonal antibody, is app...

    Authors: Giovanni Grignani, Vanna Chiarion Sileni, Carmine Pinto, Roberta Depenni, Nicola Fazio, Luca Galli, Dario Giuffrida, Carlo Carnaghi, Domenico Ciliberto, Domenico C. Corsi, Paola Queirolo, Elena Benincasa, Filippo Venturini, Gennaro Fazzi, Nuno Costa and Paolo Antonio Ascierto
    Citation: Journal of Translational Medicine 2021 19:70
  11. Clinical risk scores and machine learning models based on routine laboratory values could assist in automated early identification of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients at ri...

    Authors: Verena Schöning, Evangelia Liakoni, Christine Baumgartner, Aristomenis K. Exadaktylos, Wolf E. Hautz, Andrew Atkinson and Felix Hammann
    Citation: Journal of Translational Medicine 2021 19:56
  12. Recent preclinical data suggest that there may be therapeutic synergy between immune checkpoint blockade and inhibition of the coagulation cascade. Here, we investigate whether patients who received immune che...

    Authors: Paul Johannet, Amelia Sawyers, Nicholas Gulati, Douglas Donnelly, Samuel Kozloff, Yingzhi Qian, Alfredo Floristan, Eva Hernando, Judy Zhong and Iman Osman
    Citation: Journal of Translational Medicine 2021 19:47
  13. Epidermal growth factor receptor (EGFR) is frequently amplified or overexpressed in head and neck squamous cell carcinoma (HNSCC) and is a clinically validated target for the therapeutic antibody, cetuximab, i...

    Authors: Sean P. Korpela, Trista K. Hinz, Ayman Oweida, Jihye Kim, Jacob Calhoun, Robert Ferris, Raphael A. Nemenoff, Sana D. Karam, Eric T. Clambey and Lynn E. Heasley
    Citation: Journal of Translational Medicine 2021 19:43
  14. Studies carried out in vitro and in a mouse model have shown that BRAF inhibitors enhance the effects of IFN-α on BRAFV600E melanoma cells through the inhibition of ERK. Therefore, the combination of vemurafenib ...

    Authors: Ester Simeone, Giosuè Scognamiglio, Mariaelena Capone, Diana Giannarelli, Antonio M. Grimaldi, Domenico Mallardo, Gabriele Madonna, Marcello Curvietto, Assunta Esposito, Fabio Sandomenico, Francesco Sabbatino, Nicholas L. Bayless, Sarah Warren, SuFey Ong, Gerardo Botti, Keith T. Flaherty…
    Citation: Journal of Translational Medicine 2021 19:17
  15. Over the last few years, numerous clinical trials and real-world experience have provided a large amount of evidence demonstrating the potential for long-term survival with immunotherapy agents across various ...

    Authors: Paolo A. Ascierto, Lisa H. Butterfield, Katie Campbell, Bruno Daniele, Michael Dougan, Leisha A. Emens, Silvia Formenti, Filip Janku, Samir N. Khleif, Tomas Kirchhoff, Alessandro Morabito, Yana Najjar, Paul Nathan, Kunle Odunsi, Akash Patnaik, Chrystal M. Paulos…
    Citation: Journal of Translational Medicine 2021 19:13
  16. The easy access to a quick diagnosis of coronavirus disease 2019 (COVID-19) is a key point to improve the management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and to contain its spread. U...

    Authors: Leonardo Miscio, Antonio Olivieri, Francesco Labonia, Gianfranco De Feo, Paolo Chiodini, Giuseppe Portella, Luigi Atripaldi, Roberto Parrella, Rodolfo Conenna, Franco Maria Buonaguro, Ernesta Cavalcanti, Paolo Ascierto, Gerardo Botti and Attilio Bianchi
    Citation: Journal of Translational Medicine 2020 18:488
  17. The diagnosis of check-point inhibitor-related pneumonitis (CIP) relies on radiological and clinical patterns which are not specific and can mimic other conditions (cancer progression, infectious diseases or i...

    Authors: Sabino Strippoli, Livia Fucci, Antonio Negri, Daniela Putignano, Marco Luigi Cisternino, Gaetano Napoli, Ruggiero Filannino, Ivana De Risi, Angela Monica Sciacovelli and Michele Guida
    Citation: Journal of Translational Medicine 2020 18:473
  18. Cardiomyopathy is a common side effect of doxorubicin (DOX) chemotherapy. Despite intensive research efforts in the field, there is still no evidence available for routine cardioprotective prophylaxis to preve...

    Authors: Mária Lódi, Viktor Bánhegyi, Beáta Bódi, Alexandra Gyöngyösi, Árpád Kovács, Anita Árokszállási, Nazha Hamdani, Miklós Fagyas, István Édes, Zoltán Csanádi, István Czuriga, Zoltán Kisvárday, István Lekli, Péter Bai, Attila Tóth, Zoltán Papp…
    Citation: Journal of Translational Medicine 2020 18:470
  19. Information regarding characteristics and risk factors of COVID-19 amongst middle-aged (40–59 years) patients without comorbidities is scarce.

    Authors: Peng Wang, Jing Sha, Mei Meng, Cuiyan Wang, Qingchun Yao, Zhongfa Zhang, Wenqing Sun, Xingguang Wang, Guoqiang Qie, Xue Bai, Keke Liu and Yufeng Chu
    Citation: Journal of Translational Medicine 2020 18:461
  20. Ipilimumab and Nivolumab, targeting the molecules CTLA-4, PD-1, respectively,have shown efficacy against several types of cancer. Despite these results, only a small percentage of patients maintains a long-las...

    Authors: Paolo Marchetti, Andrea Botticelli, Antonio Paolo Ascierto, Giuseppe Curigliano and Diana Giannarelli
    Citation: Journal of Translational Medicine 2020 18:446
  21. Immune checkpoint inhibition (ICI) improves survival outcomes for patients with several types of cancer including metastatic melanoma (MM), but serious immune-related adverse events requiring intervention with...

    Authors: Nicholas Gulati, Douglas Donnelly, Yingzhi Qian, Una Moran, Paul Johannet, Judy Zhong and Iman Osman
    Citation: Journal of Translational Medicine 2020 18:430
  22. Interleukin-6 (IL-6) was proposed to be associated with the severity of coronavirus disease 2019 (COVID-19). The present study aimed to explore the kinetics of IL-6 levels, validate this association in COVID-1...

    Authors: Jing Zhang, Yiqun Hao, Wuling Ou, Fei Ming, Gai Liang, Yu Qian, Qian Cai, Shuang Dong, Sheng Hu, Weida Wang and Shaozhong Wei
    Citation: Journal of Translational Medicine 2020 18:406
  23. Tocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients.

    Authors: Francesco Perrone, Maria Carmela Piccirillo, Paolo Antonio Ascierto, Carlo Salvarani, Roberto Parrella, Anna Maria Marata, Patrizia Popoli, Laurenzia Ferraris, Massimiliano M. Marrocco-Trischitta, Diego Ripamonti, Francesca Binda, Paolo Bonfanti, Nicola Squillace, Francesco Castelli, Maria Lorenza Muiesan, Miriam Lichtner…
    Citation: Journal of Translational Medicine 2020 18:405

    The Correction to this article has been published in Journal of Translational Medicine 2021 19:442

  24. It is well established that thymidylate synthase inhibitors can cause cellular toxicity through uracil DNA glycosylase (UNG2)-dependent pathways. Additionally, thymidylate synthase inhibitors and HDAC inhibito...

    Authors: Meredith S. Showler and Brian P. Weiser
    Citation: Journal of Translational Medicine 2020 18:377
  25. More than seven months into the coronavirus disease -19 (COVID-19) pandemic, infection from the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has led to over 21.2 million cases and resulted in o...

    Authors: Maurice A. Canham, John D. M. Campbell and Joanne C. Mountford
    Citation: Journal of Translational Medicine 2020 18:359
  26. Severe COVID-19 infection results in a systemic inflammatory response (SIRS). This SIRS response shares similarities to the changes observed during the peri-operative period that are recognised to be associate...

    Authors: Donogh Maguire, Marylynne Woods, Conor Richards, Ross Dolan, Jesse Wilson Veitch, Wei M. J. Sim, Olivia E. H. Kemmett, David C. Milton, Sophie L. W. Randall, Ly D. Bui, Nicola Goldmann, Allan Cameron, Barry Laird, Dinesh Talwar, Ian Godber, Alan Davidson…
    Citation: Journal of Translational Medicine 2020 18:354
  27. Unresectable or metastatic vulvar cancer has relatively poor outcomes despite chemotherapy-sensitized radiation therapy and combination cytotoxic therapy. Despite the virus-associated and immunogenic nature of...

    Authors: Oladapo Yeku, Andrea L. Russo, Hang Lee and David Spriggs
    Citation: Journal of Translational Medicine 2020 18:350
  28. The melanoma treatment landscape changed in 2011 with the approval of the first anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 checkpoint inhibitor and of the first BRAF-targeted monoclonal antibody, ...

    Authors: Paolo A. Ascierto, Igor Puzanov, Sanjiv S. Agarwala, Christian Blank, Richard D. Carvajal, Sandra Demaria, Reinhard Dummer, Marc Ernstoff, Soldano Ferrone, Bernard A. Fox, Thomas F. Gajewski, Claus Garbe, Patrick Hwu, Roger S. Lo, Georgina V. Long, Jason J. Luke…
    Citation: Journal of Translational Medicine 2020 18:346
  29. Antibody based cancer therapies have achieved convincing success rates combining enhanced tumor specificity and reduced side effects in patients. Trastuzumab that targets the human epidermal growth factor rela...

    Authors: Anja Kathrin Wege, Nicole Kirchhammer, Linda Veronique Kazandjian, Sandra Prassl, Michael Brandt, Gerhard Piendl, Olaf Ortmann, Stephan Fischer and Gero Brockhoff
    Citation: Journal of Translational Medicine 2020 18:316
  30. In the rapidly evolving coronavirus disease 2019 (COVID-19) outbreak, inherent literature has been increasing at an impressive rate. Such a dynamic scenario imposes the necessity to define a new framework for ...

    Authors: Maddalena Barba, Eriseld Krasniqi, Gennaro Ciliberto and Patrizia Vici
    Citation: Journal of Translational Medicine 2020 18:315
  31. Necrotizing enterocolitis (NEC) is one of the most severe complications in very preterm infants, but there are currently no accepted methods to prevent NEC. Studies have shown that erythropoietin (EPO) has the...

    Authors: Yong Wang, Juan Song, Huiqing Sun, Falin Xu, Kenan Li, Chunxia Nie, Xiaoli Zhang, Xirui Peng, Lei Xia, Ziyun Shen, Xiao Yuan, Shan Zhang, Xue Ding, Yaodong Zhang, Wenqing Kang, Liling Qian…
    Citation: Journal of Translational Medicine 2020 18:308
  32. We sought to identify patient subgroups with distinct postprogression overall survival (ppOS) outcomes and investigate the impact of original treatment assignment and initial postprogression treatment (ppRx) o...

    Authors: Paolo A. Ascierto, Antoni Ribas, James Larkin, Grant A. McArthur, Karl D. Lewis, Axel Hauschild, Keith T. Flaherty, Edward McKenna, Qian Zhu, Yong Mun and Brigitte Dréno
    Citation: Journal of Translational Medicine 2020 18:294
  33. Immunotherapy with checkpoint inhibitors (CPI) targeting PD-1 or CTLA-4 has emerged as an important treatment modality for several cancer forms. In hormone receptor positive breast cancer (HR + BC), this thera...

    Authors: J. A. Kyte, N. K. Andresen, H. G. Russnes, S. Ø. Fretland, R. S. Falk, O. C. Lingjærde and B. Naume
    Citation: Journal of Translational Medicine 2020 18:269
  34. The recent global pandemic has placed a high priority on identifying drugs to prevent or lessen clinical infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), caused by Coronavirus disease...

    Authors: Jason Kim, Jenny Zhang, Yoonjeong Cha, Sarah Kolitz, Jason Funt, Renan Escalante Chong, Scott Barrett, Rebecca Kusko, Ben Zeskind and Howard Kaufman
    Citation: Journal of Translational Medicine 2020 18:257
  35. Immunotherapy with checkpoint inhibitors (CI) represents an important novel development in cancer treatment. Metastatic triple-negative breast cancer (mTNBC) is incurable, with a median survival of only ~ 13 m...

    Authors: J. A. Kyte, A. Røssevold, R. S. Falk and B. Naume
    Citation: Journal of Translational Medicine 2020 18:252
  36. Immune checkpoint inhibitors (ICIs) have been increasingly applied in the treatment of several kinds of malignancies. Some clinical demographic characteristics were reported to be associated with the ICIs effi...

    Authors: Yue An, Zhonghua Wu, Ningning Wang, Zhidong Yang, Yue Li, Boyang Xu and Mingjun Sun
    Citation: Journal of Translational Medicine 2020 18:235
  37. COVID-19 has rapidly spread all over the world, progressing into a pandemic. This situation has urgently impelled many companies and public research institutes to concentrate their efforts on research for effe...

    Authors: Giovanni Salvatori, Laura Luberto, Mariano Maffei, Luigi Aurisicchio, Giuseppe Roscilli, Fabio Palombo and Emanuele Marra
    Citation: Journal of Translational Medicine 2020 18:222
  38. The outbreak of the novel coronavirus disease 2019 (COVID-19) and consequent social distancing practices have disrupted essential clinical research functions worldwide. Ironically, this coincides with an immed...

    Authors: Iman Osman, Paolo Cotzia, Una Moran, Douglas Donnelly, Carolina Arguelles-Grande, Sandra Mendoza and Andre Moreira
    Citation: Journal of Translational Medicine 2020 18:219

    The Correction to this article has been published in Journal of Translational Medicine 2021 19:240

  39. Immunotherapeutic regulation of the tumor microenvironment in prostate cancer patients is not understood. Most antibody immunotherapies have not succeeded in prostate cancer. We showed previously that high-ris...

    Authors: Stephen T. Ryan, Jing Zhang, Danielle N. Burner, Michael Liss, Emily Pittman, Michelle Muldong, Ahmed Shabaik, Jason Woo, Nicole Basler, Jonathan Cunha, Shabnam Shalapour, Monica V. Estrada, Michael Karin, Karen Messer, Stephen Howell, Christopher J. Kane…
    Citation: Journal of Translational Medicine 2020 18:214

    The Letter to the Editor to this article has been published in Journal of Translational Medicine 2020 18:333

  40. The COVID-19 pandemic has become the leading societal concern. The pandemic has shown that the public health concern is not only a medical problem, but also affects society as a whole; so, it has also become t...

    Authors: Negar Moradian, Hans D. Ochs, Constantine Sedikies, Michael R. Hamblin, Carlos A. Camargo Jr., J. Alfredo Martinez, Jacob D. Biamonte, Mohammad Abdollahi, Pedro J. Torres, Juan J. Nieto, Shuji Ogino, John F. Seymour, Ajith Abraham, Valentina Cauda, Sudhir Gupta, Seeram Ramakrishna…
    Citation: Journal of Translational Medicine 2020 18:205
  41. Most mutations in melanoma affect one critical amino acid on BRAF gene, resulting in the V600E substitution. Patient management is often based on the use of specific inhibitors targeting this mutation.

    Authors: Muna Al Hashmi, Konduru S. Sastry, Lee Silcock, Lotfi Chouchane, Valentina Mattei, Nicola James, Rebecca Mathew, Davide Bedognetti, Valeria De Giorgi, Daniela Murtas, Wei Liu, Aouatef Chouchane, Ramzi Temanni, Barbara Seliger, Ena Wang, Francesco M. Marincola…
    Citation: Journal of Translational Medicine 2020 18:192
  42. The Great Debate session at the 2019 Melanoma Bridge congress (December 5-7, Naples, Italy) featured counterpoint views from experts on five topical issues in melanoma. These were whether to choose local intra...

    Authors: Paolo A. Ascierto, Sanjiv S. Agarwala, Alexander Eggermont, Jeffrey E. Gershenwald, Jean-Jacques Grob, Omid Hamid, Olivier Michielin, Michael Postow, Igor Puzanov, Hassane M. Zarour, Corrado Caracò and Alessandro Testori
    Citation: Journal of Translational Medicine 2020 18:171
  43. Human telomerase reverse transcriptase (hTERT) is an antigen that may represent a target for a novel anti-cancer strategy. A pilot, phase I study tested the safety and feasibility of a prime-boost immunization...

    Authors: Luigi Aurisicchio, Arthur Fridman, David Mauro, Rose Sheloditna, Alberto Chiappori, Ansuman Bagchi and Gennaro Ciliberto
    Citation: Journal of Translational Medicine 2020 18:39
  44. Melanoma patients with metastatic growth in the meninges have poor prognosis and few treatment options. Although treatment with BRAF inhibitors or immune checkpoint inhibitors has provided promising results, m...

    Authors: Trude G. Simonsen, Jon-Vidar Gaustad and Einar K. Rofstad
    Citation: Journal of Translational Medicine 2020 18:13
  45. Tumor cells have evolved complex strategies to escape immune surveillance, a process which involves NK cells and T lymphocytes, and various immunological factors. Indeed, tumor cells recruit immunosuppressive ...

    Authors: Raquel Alves, Stephanie E. B. McArdle, Jayakumar Vadakekolathu, Ana Cristina Gonçalves, Paulo Freitas-Tavares, Amélia Pereira, Antonio M. Almeida, Ana Bela Sarmento-Ribeiro and Sergio Rutella
    Citation: Journal of Translational Medicine 2020 18:2
  46. Programmed cell death ligand-1 (PD-L1) expression on tumor cells (TCs) is associated with improved survival in patients with head and neck squamous cell carcinoma (HNSCC) treated with immunotherapy, although i...

    Authors: Sara I. Pai, Ezra E. W. Cohen, Derrick Lin, George Fountzilas, Edward S. Kim, Holger Mehlhorn, Neus Baste, Daniel Clayburgh, Loren Lipworth, Carlo Resteghini, Nawar Shara, Takashi Fujii, Jun Zhang, Michael Stokes, Huifen Wang, Philip Twumasi-Ankrah…
    Citation: Journal of Translational Medicine 2019 17:429

Annual Journal Metrics